Asked by: Joshua Reynolds (Liberal Democrat - Maidenhead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of the UK-US Pharmaceuticals Deal concluded in December 2025 on (a) NHS procurement costs and (b) consumer access to affordable medicines before any provisions of that Deal take effect.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
There are no current plans to publish an impact assessment or modelling on the United Kingdom and United States’ pharmaceutical trade deal. Further detail on the deal will be shared in due course.
Tens of thousands of National Health Service patients will benefit from this deal, which will secure and expand access to vital drugs, and thereby safeguard our medicines supply chain.
Costs will start smaller but will increase over time as the National Institute for Health and Care Excellence (NICE) approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. The final costs will depend on which medicines NICE recommends and the actual uptake of these.
This deal is a vital investment that builds on the strength of our NHS and world leading life sciences sector, without taking essential funding from our frontline NHS services.
Asked by: Lord Freyberg (Crossbench - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the importance of prompt, large-scale molecular testing to the efficiency of commercial clinical trial recruitment, particularly in cancer; and of how prompt, large-scale molecular testing influences industry decisions on country prioritisation and site selection, in particular for late-phase trials conducted in England.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in the Life Sciences Sector Plan, the Government aims to double commercial interventional trial participants by 2026, and again by 2029.
Access to large-scale molecular testing will play a role in delivering against this aim, since molecular testing can identify patients with specific biomarkers and target them into clinical trials. More consistent and equitable genomic testing across England will encourage commercial sponsors to place their clinical trials at research sites in the United Kingdom.
To deliver this, we are embedding genomic testing as routine practice within the NHS Genomic Medicine Service and its workforce. This includes seven NHS Genomic Laboratory Hubs delivering comprehensive genomic testing and analysis, such as whole genome sequencing, as part of routine care. The Genomics Education Programme is responsible for upskilling the entire multi-professional, multi-specialty National Health Service workforce in genomics.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring that the patient population can be more easily contacted by researchers.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to expand brain cancer trials in the UK.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to ensuring that all patients, including those with brain cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
The Department is committed to turbocharging clinical research and delivering better patient care, to make the United Kingdom a world-leading destination for clinical research. We are working to fast-track clinical trials to drive global investment into life sciences, improve health outcomes, and accelerate the development of medicines and therapies of the future, including treatments for brain cancer.
In December 2025, the Department, through the National Institute for Health and Care Research, announced an initial £13.7 million investment in the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. Significant further funding is due to be awarded shortly. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring the patient population can be more easily contacted by researchers.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate his Department has made of total public outgoings on additional medicine spending over the Spending Review period.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
In relation to the recently announced plans to increase the standard cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE), costs will start smaller but will increase over time as NICE approves more life improving and life-saving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. The final costs will depend on which medicines NICE recommends and the actual uptake of these.
We have no plans to publish an impact assessment or details of the modelling which led to this estimated figure. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences without taking essential funding from our frontline NHS services.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the total outgoings by the health service on additional medicine spending over the Spending Review period.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
In relation to the recently announced plans to increase the standard cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE), costs will start smaller but will increase over time as NICE approves more life improving and life-saving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. The final costs will depend on which medicines NICE recommends and the actual uptake of these.
We have no plans to publish an impact assessment or details of the modelling which led to this estimated figure. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences without taking essential funding from our frontline NHS services.
Asked by: Danny Chambers (Liberal Democrat - Winchester)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how his Department calculated the cost of additional spending on medicines over the spending review period.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
In relation to the recently announced plans to increase the standard cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE), costs will start smaller but will increase over time as NICE approves more life improving and life-saving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. The final costs will depend on which medicines NICE recommends and the actual uptake of these.
We have no plans to publish an impact assessment or details of the modelling which led to this estimated figure. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences without taking essential funding from our frontline NHS services.
Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, what steps he is taking to support the creation of well-paid jobs in a) Newcastle-under-Lyme and b) Staffordshire.
Answered by Blair McDougall - Parliamentary Under Secretary of State (Department for Business and Trade)
The Department for Business and Trade is supporting the creation of jobs and opportunities across the UK, including in Staffordshire and Newcastle-under-Lyme, by championing free trade agreements, supporting small and medium sized enterprises to export, securing foreign investment, developing the UK’s Modern Industrial Strategy and investing in growth sectors like life sciences, advanced manufacturing and digital technologies.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has conducted an assessment of the potential impact of the UK-USA pharmaceutical deal on frontline NHS services.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Every patient deserves access to the best possible treatment. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.
Costs will start smaller but will increase over time as the National Institute for Health and Care Excellence (NICE) approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. But the final costs will clearly depend on which medicines NICE decides to approve and the actual uptake of these. This is not something that we can pre-empt at this time as it depends on which drugs come to market, and which are assessed as approved for use on the NHS accordingly.
At the Spending Review we delivered record real terms increase for day-to-day spending for the NHS in England up to April 2029. This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessments his department has made of the predicted total cost of UK-US pharmaceutical deal on the NHS budget.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Every patient deserves access to the best possible treatment. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.
Costs will start smaller but will increase over time as the National Institute for Health and Care Excellence (NICE) approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. But the final costs will clearly depend on which medicines NICE decides to approve and the actual uptake of these. This is not something that we can pre-empt at this time as it depends on which drugs come to market, and which are assessed as approved for use on the NHS accordingly.
At the Spending Review we delivered record real terms increase for day-to-day spending for the NHS in England up to April 2029. This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how he plans to fund the UK-US pharmaceutical deal.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Every patient deserves access to the best possible treatment. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.
Costs will start smaller but will increase over time as the National Institute for Health and Care Excellence (NICE) approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. But the final costs will clearly depend on which medicines NICE decides to approve and the actual uptake of these. This is not something that we can pre-empt at this time as it depends on which drugs come to market, and which are assessed as approved for use on the NHS accordingly.
At the Spending Review we delivered record real terms increase for day-to-day spending for the NHS in England up to April 2029. This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.